Pfizer and Astellas Announce Breakthrough in Bladder Cancer Treatment

An announcement from Astellas Pharma ( (JP:4503) ) is now available.

Pfizer and Astellas Pharma have announced positive results from their Phase 3 EV-303 clinical trial, which evaluated the combination of PADCEV and KEYTRUDA for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. The trial demonstrated significant improvements in survival rates, marking a potential new standard of care for this patient population and addressing a critical unmet need.

The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.

More about Astellas Pharma

Astellas Pharma Inc. is a pharmaceutical company that focuses on the development of innovative drugs, particularly in the field of oncology. The company collaborates with other industry leaders, such as Pfizer, to advance treatment options for various cancers.

Average Trading Volume: 6,239,536

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen2909.1B

For a thorough assessment of 4503 stock, go to TipRanks’ Stock Analysis page.